Latest 10-Q quarterly reports

Heartland Express Inc. reported a return to net income in the second quarter of 2026, driven by improved freight volumes and pricing, alongside strategic asset disposals, despite a significant increase in fuel prices.

AirSculpt Technologies reported a decrease in revenue and an increase in operating expenses for the second quarter of 2026, leading to a net loss, while also addressing material weaknesses in internal controls.

Gencor Industries' Q3 results show a significant increase in net revenue and operating income, driven by higher contract equipment sales and improved gross margins.

MNTN, Inc. announced a 20.6% increase in revenue for the second quarter of 2026, driven by growth in its PTV platform, alongside a significant reduction in net loss.

NeOnc Technologies Holdings, Inc. has amended its advisory agreement with AFH Holding & Advisory, LLC, establishing a new annual fee structure based on fully diluted market capitalization, while the company continues to grapple with significant operating losses and substantial doubt regarding its ability to continue as a going concern.

MAIA Biotechnology, Inc. reports substantial progress in its Phase 2 and Phase 3 oncology trials, bolstered by significant capital raises, while continuing to navigate the inherent financial challenges of drug development.

ASPAC II Acquisition Corp. reports continued operational inactivity and net losses for Q2 2026, with its deadline to complete a business combination extended to August 5, 2027, while facing substantial doubt regarding its going concern status.

Veru Inc. reports Q3 2026 results, highlighting progress in enobosarm development and a significant cash position, but also acknowledges substantial doubt regarding its ability to continue as a going concern.

Quanterix Corporation's Q2 2026 Form 10-Q reveals revenue growth driven by acquisitions, but also a substantial goodwill impairment charge and a revised cash flow breakeven timeline.

Envoy Medical, Inc. filed its Q2 2026 Form 10-Q, detailing continued net losses and progress in its Acclaim CI clinical trials, while facing substantial doubt regarding its going concern status.

Sonida Senior Living's Q2 2026 Form 10-Q reveals substantial revenue growth driven by the CHP merger, but also significant net losses and increased debt, highlighting integration challenges.

International Seaways, Inc. announced a substantial increase in its Q2 2026 income from vessel operations, driven by higher charter rates and strategic fleet growth.

Tonix Pharmaceuticals Holding Corp. reported a substantial increase in net loss for the second quarter of 2026, driven by higher research and development and selling, general, and administrative expenses, while revenue saw significant growth.

Conduent Incorporated (CNDT) filed its Q2 2026 Form 10-Q, detailing a net loss of $116 million on revenue of $531 million, impacted by ongoing divestitures and restructuring costs.

Latch, Inc. (DOOR) filed its Q2 2026 Form 10-Q, revealing an 18.1% year-over-year revenue decrease to $15.6 million, a net loss of $6.9 million, and ongoing material weaknesses in internal controls.

Heron Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing a net loss of $5.5 million, a decline in oncology sales, and ongoing efforts to regain Nasdaq's minimum bid price compliance.

Apogee Therapeutics reports positive clinical data for its lead candidate, zumilokibart, and progress on its planned acquisition by AbbVie, while navigating substantial R&D expenses.

MoonLake Immunotherapeutics' Q2 2026 Form 10-Q details positive clinical trial updates for Sonelokimab (SLK) and a strong cash position, while acknowledging continued operating losses.

Aeries Technology, Inc. posted a 43% year-over-year revenue increase for Q1 2027, driven by new clients and one-time fees, while successfully regaining Nasdaq bid price compliance.

Athene Holding Ltd. announced robust Q2 2026 financial results, with revenues up significantly year-over-year, driven by strong investment performance and increased premiums, though higher expenses and a large tax provision impacted net income.

Keel Infrastructure Corp. (formerly Bitfarms Ltd.) filed its Form 10-Q for the quarter ended June 30, 2026, detailing a significant revenue decrease and a net loss, alongside strategic transitions.

Apollo Global Management, Inc. (AGM) reported robust Q2 2026 results, driven by significant increases in asset management and retirement services revenues, alongside strategic acquisitions and favorable market conditions.

Silence Therapeutics plc filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued net losses and outlining the need for future capital raises.

Jade Biosciences, Inc. disclosed its second-quarter 2026 financial results, highlighting increased research and development spending and general administrative costs, alongside positive interim clinical data for its lead candidates.

N-able, Inc. announced its second quarter 2026 financial results, showcasing a 5.9% increase in total revenue to $138.2 million and a return to net income.

Opal Fuels Inc. reported a slight revenue increase in Q2 2026, but faced significant operating losses, higher interest expenses, and substantial impairment charges, indicating a challenging financial period.

Passage Bio announces a merger agreement with Remix Therapeutics, plans to wind down gene therapy programs, and reports significant operating losses and cash burn.

SIFCO Industries saw a substantial increase in net sales, primarily driven by military contracts, though higher costs impacted profitability.

Freedom Holding Corp. reported a significant increase in total revenue and net income for the first quarter of fiscal year 2026, driven by strong performance across its brokerage and banking segments.

Village Farms International, Inc. announced a 7% increase in consolidated revenues for the second quarter of 2026, driven by significant growth in international cannabis exports and improved gross margins.